The final outcome of SMARTool is a CDSS platform beyond the state of the art with integrated functionalities for clinical management of patients with suspected CAD and/or asymptomatic patients with risk factors (Fig. 1-2). The first module of CDSS is the PIM calculator of CAD presence/severity risk score. CCTA based models include the 3D coronary reconstruction, the plaque growth and CAD progression prediction, smart FFR computation and virtual stenting. They integrate the information obtained by a CT scan in terms of plaque features, quantitative measurements, virtual estimation of FFR, prediction of CAD progression and simulation of stent deployment for stent implantation procedure. The novel CDSS, combined with cost effective miniaturized devices for Point of Care Testing such as Lab on-chip and RNA panel kit, is expected to considerably optimise patient monitoring and CAD management, with impact on the quality, accessibility and cost-effectiveness of healthcare. The expected benefits are: 1. Benefits to the patients to gain a more accurate diagnosis, prevention/prediction and treatment of CAD and CAD related clinical events. 2. Benefits to healthcare professionals due to optimised primary and secondary prevention of CAD (less unplanned visits, re/hospitalization, etc). 3. Benefits to the healthcare system and policy makers, by re-organizing prevention, diagnosis and treatment strategies of CAD by translating multiscale modeling into practice. 4. Indirect benefits to the other actors, such as the eHealth market and medical pharma in terms of competitiveness and revenues increase. The medical software and devices industry can integrate the gained knowledge, developing software for diagnosis, prediction and treatment in other chronic diseases at high social impact.
